CA2284170C - Identification of agents for use in the treatment of alzheimer's disease - Google Patents

Identification of agents for use in the treatment of alzheimer's disease Download PDF

Info

Publication number
CA2284170C
CA2284170C CA002284170A CA2284170A CA2284170C CA 2284170 C CA2284170 C CA 2284170C CA 002284170 A CA002284170 A CA 002284170A CA 2284170 A CA2284170 A CA 2284170A CA 2284170 C CA2284170 C CA 2284170C
Authority
CA
Canada
Prior art keywords
sample
metal
sds
chelator
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002284170A
Other languages
English (en)
French (fr)
Other versions
CA2284170A1 (en
Inventor
Ashley I. Bush
Xudong Huang
Craig S. Atwood
Rudolph E. Tanzi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CA2284170A1 publication Critical patent/CA2284170A1/en
Application granted granted Critical
Publication of CA2284170C publication Critical patent/CA2284170C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
CA002284170A 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease Expired - Fee Related CA2284170C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81612297A 1997-03-11 1997-03-11
US08/816,122 1997-03-11
PCT/US1998/004683 WO1998040071A1 (en) 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2284170A1 CA2284170A1 (en) 1998-09-17
CA2284170C true CA2284170C (en) 2008-12-02

Family

ID=25219748

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284170A Expired - Fee Related CA2284170C (en) 1997-03-11 1998-03-11 Identification of agents for use in the treatment of alzheimer's disease

Country Status (5)

Country Link
EP (1) EP1007048A4 (de)
JP (1) JP2001514661A (de)
AU (1) AU748768B2 (de)
CA (1) CA2284170C (de)
WO (1) WO1998040071A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743771B2 (en) * 1995-12-29 2004-06-01 Novactyl, Inc. Methods and compositions for controlling protein assembly or aggregation
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
WO1999009981A1 (en) 1997-08-21 1999-03-04 P.N. Gerolymatos S.A. Use of phanquinone for the treatment of alzheimer's disease
JP2001519529A (ja) 1997-10-06 2001-10-23 ザ ジェネラル ホスピタル コーポレイション 遅発性ジスキネジーを予測するために薬物をスクリーニングするための方法
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
EP1115389B1 (de) 1998-09-25 2014-03-12 PhilERA New Zealand Limited Antagonisten und agonisten der fructosamin oxidase
DK1140090T3 (da) 1999-01-07 2005-04-18 Gerolymatos P N Sa Anvendelse af phanquinon til behandlingen eller hindringen af hukommelsessvigt
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
DE60043165D1 (de) * 1999-08-04 2009-11-26 Univ Southern California Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
AU2001239544A1 (en) * 2000-03-22 2001-10-03 Bf Research Institute, Inc. Image diagnosis probe based on substituted azobenzene or analogue thereof for disease attributable to amyloid accumulation and composition for image diagnosis containing the same
AUPR976401A0 (en) * 2001-12-27 2002-01-31 Alzhyme Pty Ltd Agents for the treatment of alzheimer's disease and screening methods for the same
AU2002351880B2 (en) * 2001-12-27 2007-08-30 Neuroscientific Biopharmaceuticals Pty Ltd Screening methods and the use of agents identified using the same
CN1649577A (zh) 2002-03-08 2005-08-03 普罗特米克斯公司 预防和/或治疗心血管疾病和/或相关的心衰
CA2875522A1 (en) 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
US20070185072A1 (en) * 2003-03-21 2007-08-09 Christophe Boldron Nitrogeneous polycyclic derivatives useful as chelators of metal ions and their applications
CN1849112B (zh) * 2003-09-09 2012-06-13 吉里德科学公司 治疗性脂质体
EP1694317A4 (de) * 2003-12-19 2010-05-12 Protemix Corp Ltd Kupfer-antagonisten-verbindungen
PT1778618E (pt) 2004-07-19 2014-03-04 Philera New Zealand Ltd Síntese de trietilenotetraminas
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
SG171670A1 (en) 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
US8338089B2 (en) 2006-11-20 2012-12-25 The Johns Hopkins University Method of inhibiting lentiviral infectivity utilizing zinc chelation to inhibit Vif activity
KR101595634B1 (ko) 2007-06-14 2016-02-18 갈락티카 파마슈티칼스, 인크. Rage 융합 단백질
WO2009108999A1 (en) * 2008-03-03 2009-09-11 Ross Stewart Grant Pharmaceutical formulations of resveratrol and methods of use thereof for treating cell disorders
AU2010240569A1 (en) 2009-04-20 2011-10-20 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
WO2018236221A2 (en) * 2017-06-03 2018-12-27 Can Holding B.V. Neurodegenerative peptide deposit dissolution
KR102048846B1 (ko) * 2017-11-20 2019-11-27 한국생명공학연구원 혈관 질환 치료제 및 이의 스크리닝 방법
US12521362B2 (en) * 2019-07-25 2026-01-13 Tokyo University Of Science Foundation Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434050A (en) * 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
JP3277211B2 (ja) * 1991-11-12 2002-04-22 プラナ・バイオテクノロジー・リミテッド アルツハイマー病の試験方法と治療方法
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
JPH07149668A (ja) * 1993-11-30 1995-06-13 Kanegafuchi Chem Ind Co Ltd アミロイド沈着検出用物質
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5854204A (en) * 1995-03-14 1998-12-29 Praecis Pharmaceuticals, Inc. Aβ peptides that modulate β-amyloid aggregation
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Also Published As

Publication number Publication date
CA2284170A1 (en) 1998-09-17
WO1998040071A1 (en) 1998-09-17
EP1007048A4 (de) 2004-09-22
EP1007048A1 (de) 2000-06-14
AU6548498A (en) 1998-09-29
AU748768B2 (en) 2002-06-13
JP2001514661A (ja) 2001-09-11

Similar Documents

Publication Publication Date Title
CA2284170C (en) Identification of agents for use in the treatment of alzheimer's disease
US6323218B1 (en) Agents for use in the treatment of Alzheimer's disease
WO1998040071A9 (en) Identification of agents for use in the treatment of alzheimer's disease
McLachlan Aluminium and the risk for Alzheimer's disease
Atwood et al. Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar‐affinity copper binding site on amyloid β1‐42
PL188838B1 (pl) Zastosowanie kliochinolu do wytwarzania środka farmaceutycznego i środek farmaceutyczny
US7045531B1 (en) Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
US20050112543A1 (en) Method of screening for drugs useful in treating Alzheimer's disease
US6638711B1 (en) Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
CA2379858C (en) Beta-amyloid peptide inhibitors
HK1033907B (en) Metal chelators for use in the treatment of alzheimer's disease
CA2601285A1 (en) Agents for use in the treatment of amyloidosis
Huckle PBT-1 Prana biotechnology
Curtain et al. Aβ Metallobiology and the Development of Novel Metal-Protein Attenuating Compounds (MPACs) for Alzheimer's Disease
JP2004506915A (ja) 白内障を阻害又は促進する物質を同定する方法及びその使用
Okafor et al. Next-generation Cu (II) selective peptide shuttles prevent Cu (Aβ)-induced toxicity and microglial activation in organotypic hippocampal slices
Khan Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Aβ42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease
AU780380B2 (en) Beta-amyloid peptide inhibitors
White et al. The Metallobiology of Alzheimer's Disease: From Bench to Clinic.
Summers 8-Hydroxyquinoline Copper Complexes in the Treatment of Neurodegenerative Disease
Guzmán Oxidative stress and the amyloid beta peptide in Alzheimer's disease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed